Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients.

Orit ItzhakiElad JacobyAbraham NissaniMichal LeviArnon NaglerAdva KubiKarin BrezingerHadar BrayerLi-At ZeltzerMeir RozenbaumHelly VernitskyGal MarkelAmos TorenAbraham AvigdorJacob SchachterMichal J Besser

Published in: Journal for immunotherapy of cancer (2020)

ClinicalTrials.gov; CAR-T: NCT02772198, First posted: May 13, 2016; TIL: NCT00287131, First posted: February 6, 2006.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
prognostic factors
single cell
peritoneal dialysis
optic nerve
stem cells
patient reported
clinical evaluation